Xenon Pharmaceuticals Inc (XENE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.98B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xenon Pharmaceuticals Inc (XENE) Stock Forecast
Analysts expect Xenon Pharmaceuticals (XENE) to earn -$4.57 per share in the fiscal year ending Dec 31, 2026, on revenue of $500000. Of 18 analysts, 17 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 16.7% |
| Buy | 14 | 77.8% |
| Hold | 1 | 5.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 6560.0%.
- Fiscal year ending Dec 31, 2026
- -$4.57
- EPS consensus, revenue $500000
- Fiscal year ending Dec 31, 2027
- -$4.62
- EPS consensus, revenue $33.30M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.57 | -$4.73 to -$4.47 | 9 | $500000 | N/A | 10 |
| Dec 31, 2027 | -$4.62 | -$5.45 to -$1.90 | 13 | $33.30M | N/A | 12 |
Quarterly Estimates
The EPS consensus falls from -$1.17 for the quarter ending Dec 31, 2026 to -$1.21 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.17 | -$1.32 to -$0.89 | 18 | $919020 | N/A | 16 |
| Mar 31, 2027 | -$1.21 | -$1.30 to -$1.02 | 5 | N/A | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.63.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.57 | -$4.63 | -$4.63 | -$4.63 | -$4.63 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.62 | -$4.70 | -$4.72 | -$4.80 | -$4.87 | N/A |
| Quarter ending Mar 31, 2027 | -$1.21 | -$1.25 | -$1.25 | -$1.25 | -$1.25 | N/A |
Frequently Asked Questions About XENE
What is the XENE stock forecast?
Consensus analyst estimates put Xenon Pharmaceuticals's EPS at -$4.57 for the fiscal year ending Dec 31, 2026, on revenue of $500000. The consensus rating from 18 analysts is Buy.
How do analysts rate XENE stock?
Of 18 analysts covering Xenon Pharmaceuticals, 3 rate it Strong Buy, 14 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from XENE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.57, with estimates from -$4.73 to -$4.47 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.62, with estimates from -$5.45 to -$1.90 from 13 analysts.
What revenue do analysts expect from Xenon Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $500000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $33.30M.
How many analysts cover XENE?
18 analysts rate Xenon Pharmaceuticals stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
XENE pages: Overview, Earnings, Forecast, Financials, Competitors